News | November 03, 2014

SCAI Publishes Consensus Statement on Use of Left Ventriculography

Variation and significant changes in use reflect need for evidence-based expert consensus

November 3, 2014 – Once a common procedure, left ventriculography’s role in assessing heart disease has evolved considerably over the decades, leading to significant variations in use. A new expert consensus statement e-published by the Society for Cardiovascular Angiography and Interventions (SCAI) recommends optimal uses for left ventriculography, with the goal of more standardized use of the test and improved quality of care for cardiac patients.

Left ventriculography is a test in which contrast dye is injected in the heart’s left ventricle through a catheter to aid in capturing images of blood flow out of the left ventricle. The imaging technique was refined in the 1960s and 1970s and became the gold standard for assessing left ventricle function. But newer imaging technology – including cardiac magnetic resonance imaging (MRI), echocardiography and cardiac computed tomographic angiography (CCTA)—has led to reduced use of the test. Use today varies widely both geographically and within hospitals, and there were previously no specific guidelines to aid interventional cardiologists in performing left ventriculography at the time of coronary angiography or left heart catheterization.

“Although use of left ventriculography has declined, there are times when it continues to be a good option for some patients. Previously, no guidelines existed to help physicians understand when and how to use it,” said Osvaldo S. Gigliotti, M.D., FSCAI, the document’s lead author. “The new consensus statement fills the void for guidance on when left ventriculography is the appropriate assessment tool and how it compares to newer imaging tests.”

The paper reviews several uses for left ventriculography, including measurement of ejection fraction, an assessment of how much blood leaves the heart with each pump; identification of defects in the motion of the heart wall; and measurement of ventricle volume in patients with heart valve defects. Left ventriculography is also useful for identifying aneurysms in the left ventricle and septal defects, which are openings between the heart’s chambers.

Authors also discussed alternative imaging techniques, including cardiac MRI, echocardiography, radionuclide ventriculography and CCTA. Echocardiography has become the most commonly used alternate tool for left ventricle assessment, due to its real-time imaging, portability and widespread availability, and because it does not expose the patient to radiation as left ventriculography does.

Echocardiography is also preferred for most pediatric patients. However, left ventriculography remains the best option for children with septal defects, and those with significant vessel abnormalities.

“When compared to other imaging options, left ventriculography should be performed selectively and avoided when adequate alternatives are available,” said Gigliotti. “But there are cases where left ventriculography is essential, such as when a catheter-based device is used to close a septal defect.”

The paper also discusses potential complications and proper technique for left ventriculography. It recommends delivery of contrast dye using power injection, use of a multi-sidehole catheter and sufficient contrast volumes; angulated views to best visualize the heart; positioning the left ventricle in the isocenter of the fluoroscopy system; and having patients hold their breath to minimize motion.

The paper, titled “Optimal Use of Left Ventriculography at the Time of Cardiac Catheterization: A Consensus Statement from the Society for Cardiovascular Angiography and Intervention (SCAI),” is e-published in Catheterization and Cardiovascular Interventions.

For more information: www.scai.org

Related Content

FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Cook Medical Recalls Transseptal Needle Due to Risk of Detached Plastic Fragments
News | Cath Lab | March 20, 2019
March 20, 2019 — Cook Medical is recalling one lot of its...
DABRA Excimer Laser System Demonstrates Success in Treating PAD
News | Cath Lab | February 27, 2019
Ra Medical Systems Inc. announced a 98 percent success rate in the results from a 52-patient study using the company’s...
Edwards Lifesciences Recalls Swan-Ganz hemodynamic catheters.
Feature | Cath Lab | February 06, 2019
Edwards Lifesciences is recalling its 131F7, 131F7J, 131F7P, 131VF7P, 151F7 Swan-Ganz Thermodilution Catheters manufa
Scientists Discover New Heart Attack Repair Pathway

A macrophage immune cell, with a dead cell (pink) that has been eaten, and a mitochondrion (green) between the dead cell and the nucleus. The study’s findings indicate that what the macrophage eats is taken up by the mitochondrion, which in turn communicates with the nucleus to activate the macrophage to promote tissue repair. Image courtesy of Northwestern Medicine.

News | Cath Lab | January 30, 2019
Northwestern Medicine scientists have discovered a novel signaling pathway that promotes healing after a heart attack....
Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
Overlay Init